Literature DB >> 30679159

Sulforaphane Suppresses the Growth of Triple-negative Breast Cancer Stem-like Cells In vitro and In vivo.

Nadia P Castro1, Maria C Rangel1, Anand S Merchant2, Gabriel MacKinnon1, Frank Cuttitta1, David S Salomon1, Young S Kim3.   

Abstract

Triple-negative breast cancer (TNBC) represents the poorest prognosis among all of breast cancer subtypes with no currently available effective therapy. In this study, we hypothesized that sulforaphane, a dietary component abundant in broccoli and its sprouts, can inhibit malignant cell proliferation and tumor sphere formation of cancer stem-like cells (CSC) in TNBC. CSC population was isolated using FACS analysis with the combined stem cell surface markers, CD44+/CD24-/CD49f+ The effect of sulforaphane on a stem-related embryonic oncogene CRIPTO-1/TDGF1 (CR1) was evaluated via ELISA. In vivo, BalbC/nude mice were supplemented with sulforaphane before and after TNBC cell inoculation (daily intraperitoneal injection of 50 mg sulforaphane/kg for 5 and 3 weeks, respectively), and the effects of sulforaphane during mammary tumor initiation and growth were accessed with NanoString gene analysis. We found that sulforaphane can inhibit cell proliferation and mammosphere formation of CSCs in TNBC. Further analysis of gene expression in these TNBC tumor cells revealed that sulforaphane significantly decreases the expression of cancer-specific CR1, CRIPTO-3/TDGF1P3 (CR3, a homologue of CR1), and various stem cell markers including Nanog, aldehyde dehydrogenase 1A1 (ALDH1A1), Wnt3, and Notch4. Our results suggest that sulforaphane may control the malignant proliferation of CSCs in TNBC via Cripto-mediated pathway by either suppressing its expression and/or by inhibiting Cripto/Alk4 protein complex formation. Thus, the use of sulforaphane for chemoprevention of TNBC is plausible and warrants further clinical evaluation. ©2019 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30679159      PMCID: PMC6425935          DOI: 10.1158/1940-6207.CAPR-18-0241

Source DB:  PubMed          Journal:  Cancer Prev Res (Phila)        ISSN: 1940-6215


  35 in total

1.  Sulforaphane inhibits the growth of KPL-1 human breast cancer cells in vitro and suppresses the growth and metastasis of orthotopically transplanted KPL-1 cells in female athymic mice.

Authors:  Sayaka Kanematsu; Katsuhiko Yoshizawa; Norihisa Uehara; Hisanori Miki; Tomo Sasaki; Maki Kuro; Yen-Chang Lai; Ayako Kimura; Takashi Yuri; Airo Tsubura
Journal:  Oncol Rep       Date:  2011-05-20       Impact factor: 3.906

2.  Germ cell nuclear factor is a repressor of CRIPTO-1 and CRIPTO-3.

Authors:  Moritz Hentschke; Ingo Kurth; Uwe Borgmeyer; Christian A Hübner
Journal:  J Biol Chem       Date:  2006-09-05       Impact factor: 5.157

Review 3.  Triple negative breast cancer cell lines: one tool in the search for better treatment of triple negative breast cancer.

Authors:  Kathryn J Chavez; Sireesha V Garimella; Stanley Lipkowitz
Journal:  Breast Dis       Date:  2010

4.  The transcription factor Nrf2 is a therapeutic target against brain inflammation.

Authors:  Nadia G Innamorato; Ana I Rojo; Angel J García-Yagüe; Masayuki Yamamoto; María L de Ceballos; Antonio Cuadrado
Journal:  J Immunol       Date:  2008-07-01       Impact factor: 5.422

5.  Sulforaphane regulates self-renewal of pancreatic cancer stem cells through the modulation of Sonic hedgehog-GLI pathway.

Authors:  Shih-Hui Li; Junsheng Fu; Dara Nall Watkins; Rakesh K Srivastava; Sharmila Shankar
Journal:  Mol Cell Biochem       Date:  2012-11-06       Impact factor: 3.396

6.  Regulation of human Cripto-1 expression by nuclear receptors and DNA promoter methylation in human embryonal and breast cancer cells.

Authors:  Caterina Bianco; Nadia P Castro; Christina Baraty; Kelly Rollman; Natalie Held; Maria Cristina Rangel; Hideaki Karasawa; Monica Gonzales; Luigi Strizzi; David S Salomon
Journal:  J Cell Physiol       Date:  2013-06       Impact factor: 6.384

7.  Emerging roles of nodal and Cripto-1: from embryogenesis to breast cancer progression.

Authors:  Luigi Strizzi; Lynne-Marie Postovit; Naira V Margaryan; Elisabeth A Seftor; Daniel E Abbott; Richard E B Seftor; David S Salomon; Mary J C Hendrix
Journal:  Breast Dis       Date:  2008

8.  Sulforaphane enhances the anticancer activity of taxanes against triple negative breast cancer by killing cancer stem cells.

Authors:  Joseph P Burnett; Gi Lim; Yanyan Li; Ronak B Shah; Rebekah Lim; Hayley J Paholak; Sean P McDermott; Lichao Sun; Yasuhiro Tsume; Shuhua Bai; Max S Wicha; Duxin Sun; Tao Zhang
Journal:  Cancer Lett       Date:  2017-02-27       Impact factor: 8.679

9.  Regulation of breast cancer stem cell activity by signaling through the Notch4 receptor.

Authors:  Hannah Harrison; Gillian Farnie; Sacha J Howell; Rebecca E Rock; Spyros Stylianou; Keith R Brennan; Nigel J Bundred; Robert B Clarke
Journal:  Cancer Res       Date:  2010-01-12       Impact factor: 12.701

10.  Characterization of the CD49f+/CD44+/CD24- single-cell derived stem cell population in basal-like DCIS cells.

Authors:  Nadire Duru; Ramkishore Gernapudi; Pang-Kuo Lo; Yuan Yao; Benjamin Wolfson; Yongshu Zhang; Qun Zhou
Journal:  Oncotarget       Date:  2016-07-26
View more
  22 in total

1.  Growth inhibitory efficacy and anti-aromatase activity of Tabebuia avellanedae in a model for post-menopausal Luminal A breast cancer.

Authors:  Nitin Telang; Hareesh B Nair; George Y C Wong
Journal:  Biomed Rep       Date:  2019-10-03

2.  Fenretinide, Tocilizumab, and Reparixin Provide Multifaceted Disruption of Oral Squamous Cell Carcinoma Stem Cell Properties: Implications for Tertiary Chemoprevention.

Authors:  Susan R Mallery; Daren Wang; Brian Santiago; Ping Pei; Caroline Bissonnette; Jayanetti Asiri Jayawardena; Steven P Schwendeman; Richard Spinney; James Lang
Journal:  Mol Cancer Ther       Date:  2019-09-12       Impact factor: 6.261

Review 3.  Stem cell models for genetically predisposed colon cancer.

Authors:  Nitin Telang
Journal:  Oncol Lett       Date:  2020-08-20       Impact factor: 2.967

4.  A Novel Sulforaphane-Regulated Gene Network in Suppression of Breast Cancer-Induced Osteolytic Bone Resorption.

Authors:  Subrata K Pore; Eun-Ryeong Hahm; Su-Hyeong Kim; Krishna B Singh; Lea Nyiranshuti; Joseph D Latoche; Carolyn J Anderson; Juraj Adamik; Deborah L Galson; Kurt R Weiss; Rebecca J Watters; Boeun Lee; Prashant N Kumta; Shivendra V Singh
Journal:  Mol Cancer Ther       Date:  2019-11-29       Impact factor: 6.261

Review 5.  Metabolic Strategies for Inhibiting Cancer Development.

Authors:  Philippe Icard; Mauro Loi; Zherui Wu; Antonin Ginguay; Hubert Lincet; Edouard Robin; Antoine Coquerel; Diana Berzan; Ludovic Fournel; Marco Alifano
Journal:  Adv Nutr       Date:  2021-07-30       Impact factor: 8.701

Review 6.  Notch Signalling in Breast Development and Cancer.

Authors:  Abigail Edwards; Keith Brennan
Journal:  Front Cell Dev Biol       Date:  2021-07-06

Review 7.  A Multidisciplinary Review of the Roles of Cripto in the Scientific Literature Through a Bibliometric Analysis of its Biological Roles.

Authors:  Elisa Rodrigues Sousa; Eugenio Zoni; Sofia Karkampouna; Federico La Manna; Peter C Gray; Marta De Menna; Marianna Kruithof-de Julio
Journal:  Cancers (Basel)       Date:  2020-06-05       Impact factor: 6.639

Review 8.  Natural and herbal compounds targeting breast cancer, a review based on cancer stem cells.

Authors:  Azam Bozorgi; Saber Khazaei; Abbasali Khademi; Mozafar Khazaei
Journal:  Iran J Basic Med Sci       Date:  2020-08       Impact factor: 2.699

Review 9.  Dietary Phytochemicals Targeting Cancer Stem Cells.

Authors:  Alena Liskova; Peter Kubatka; Marek Samec; Pavol Zubor; Milos Mlyncek; Tibor Bielik; Samson Mathews Samuel; Anthony Zulli; Taeg Kyu Kwon; Dietrich Büsselberg
Journal:  Molecules       Date:  2019-03-04       Impact factor: 4.411

10.  Isolation and Characterization of Chemo-Resistant Stem Cells from a Mouse Model of Hereditary Non-Polyposis Colon Cancer.

Authors:  Nitin Telang
Journal:  Stem Cells Cloning       Date:  2021-06-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.